Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | XmAb808 |
Synonyms | |
Therapy Description |
XmAb808 is a bispecific antibody that targets CD276 (B7-H3) on tumor cells and CD28 expressed on T-lymphocytes, which potentially leads to enhanced antitumor immune response (Journal for ImmunoTherapy of Cancer 2023;11). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
XmAb808 | XmAb-808|XmAb 808 | CD276 Antibody 16 | XmAb808 is a bispecific antibody that targets CD276 (B7-H3) on tumor cells and CD28 expressed on T-lymphocytes, which potentially leads to enhanced antitumor immune response (Journal for ImmunoTherapy of Cancer 2023;11). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|